NRC Health concluded Q4 2025 with strong financial performance, driven by disciplined execution and customer trust. The company reported a 2% quarter-over-quarter increase in total revenue to $35.2 million and a significant 13% year-over-year increase in cash flow from operations to $7.2 million. Total Recurring Contract Value (TRCV) grew 8% year-over-year, reaching $144.1 million, marking its fifth consecutive quarter of sequential growth.

NRC Health reported a net income of $5.787 million and an EPS of $0.25 for the first quarter of 2025. The company saw a sequential increase in total recurring contract value and a decline in operating expenses, reflecting progress in sales force rebuilding and organizational efficiencies.

NRC Health reported a decrease in revenue to $36.9 million compared to $38.0 million in the same quarter of the previous year. Earnings per diluted share also decreased to $0.28 from $0.36 in the prior year's quarter. The company returned $10.1 million to stockholders through dividends and stock repurchases.

NRC Health announced its Q3 2024 results, with revenue at approximately $35.8 million, a decrease from $37.9 million in the 2023 quarter. Earnings per diluted share were $0.24, also down from $0.32 in the previous year.

NRC Health announced its second quarter 2024 results, with revenue of approximately $35 million and earnings per diluted share of $0.26. The company also completed an amendment to its credit agreement and acquired NOBL Health.

NRC Health announced its first quarter 2024 results, highlighting investments in technology, sales, and service teams to launch new products and solutions. The company returned $18 million to stockholders through dividends and stock repurchases and invested $4 million in organic innovation and growth.

NRC Health reported stable revenue of $38 million for the fourth quarter of 2023 compared to the same period in 2022, with diluted earnings per share increasing to $0.36 from $0.27. The company focused on cost control and strategic capital allocation, returning $55 million to stockholders through dividends and stock repurchases during 2023.

NRC Health's third quarter 2023 saw increased new sales compared to the third quarter of 2022, driven by growth in the Human Understanding Program, which was adopted by 91 healthcare organizations. The company is focused on controlling costs and has achieved sequential quarterly operating margin improvement. NRC remains well-positioned to execute capital allocation alternatives, including innovation, growth investments, shareholder dividends, and share repurchases.

NRC Health announced its Q2 2023 results, which included a 53% increase in new sales compared to Q2 2022 and adoption of the Human Understanding Program by 39 healthcare organizations. The company's diluted earnings per share decreased to $0.29, and the company funded innovation and growth, dividend payments, and share repurchases.

NRC Health announced its first quarter 2023 results, with a focus on personalized care and expanding sales and marketing resources. The company funded innovation and growth, dividend payments, and share repurchases during the quarter. Diluted earnings per share decreased compared to the same period last year.

NRC Health reported its fourth quarter and calendar year 2022 results. The company's diluted earnings per share decreased compared to the previous year. Despite this, the company continued to grow revenue from core offerings. The company also received the Best in KLAS 2023 Award for Patient Experience Improvement.

NRC Health reported flat revenue and decreased net income and diluted earnings per share for the third quarter of 2022. Revenue was $37.7 million, net income was $8.3 million, and diluted earnings per share was $0.33.

NRC Health reported a 2% increase in revenue to $37.3 million, while operating income decreased by 6% to $11.5 million compared to the same quarter in the previous year. The company is focusing on organic growth and innovation initiatives.

NRC Health reported an 8% increase in revenue to $38.4 million, while operating income decreased by 3% to $11.7 million. Net income also decreased to $8.5 million, and diluted earnings per share fell to $0.34.

National Research Corporation reported a 10% increase in revenue to $38.3 million and a 26% increase in operating income to $12.9 million for Q4 2021 compared to Q4 2020. The operating income margin increased to 34% of revenue. The company also launched its Human Understanding Program.

National Research Corporation reported a 13% increase in revenue, reaching $37.8 million, and a 9% increase in operating income, amounting to $13.1 million for the third quarter of 2021. The company's cash balance increased to $52.5 million. Net income was $9.7 million, with diluted earnings per share of $0.38.

National Research Corporation reported a 17% increase in revenue to $36.4 million and a 32% increase in operating income to $12.2 million for the second quarter of 2021. The company's cash balance increased to $48.9 million. Revenue growth was attributed to new customer sales and increased sales to the existing client base.

National Research Corporation reported a 5% increase in revenue to $35.5 million and a 7% increase in operating income to $12.0 million for the first quarter of 2021. The company's focus remains on organic growth and strategic M&A activity.

National Research Corporation announced a 7% increase in revenue to $34.8 million, but a decrease of 15% in operating income to $10.2 million and a 6% decrease in net income to $8.2 million compared to Q4 2019.